Top Markets
Coin of the day
Galmed Pharmaceuticals Ltd. Galmed Pharmaceuticals Ltd.

Galmed Pharmaceuticals Ltd.

GLMD
Rankning i aktier #35178
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the... Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. Further, the company develops MyBiotics which is in pre-clinical trials for NASH and fibrosis. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Ramat Gan, Israel.
Aktiekurs
$0.5225
Senast synkroniserad: 2026-08-14
Marknadsvärde
$4.32M
Förändring (1 dag)
-1.60%
Förändring (1 år)
-63.72%
Land
IL
Handel Galmed Pharmaceuticals Ltd. (GLMD)

Kategori

Historik för aktiesplit för Galmed Pharmaceuticals Ltd. (GLMD)
Aktien Galmed Pharmaceuticals Ltd. (symbol: GLMD) har genomgått totalt 0 aktiesplitar.
Den senaste spliten skedde den Aug 16, 2026.
En GLMD-aktie köpt före Aug 16, 2026 motsvarar nu 0 GLMD-aktier.
Lista över aktiesplitar
År Split Multipel Kumulativ multipel
Inte tillräckligt med data för de angivna datumen.
Aktiesplitar för liknande företag eller konkurrenter
Företag Antal aktiesplitar Kumulativ multipel Land
1 x2
US
0 -
NL
0 -
CH
0 -
KR
0 -
BE